Thank you for Subscribing to Life Science Review Weekly Brief
The company has partnered with a prominent clinical facility in Israel and plans to undertake its first-in-human trial in the United States.
FREMONT, CA: "We are thrilled to have the first clinical center join our clinical trial and pleased that our innovative approach to treating AUD is well-received by the medical community. It is our intention to sign a similar agreement with a clinical center in the United States. We're committed to working with leading researchers and medical professionals to bring new and effective treatments to patients suffering the physical, mental, and social repercussions of psychiatric disorders," says Dr. Adi Zuloff-Shani, Clearmind's CEO. Clearmind Medicine, a biotechnology company focused on discovering and developing novel psychedelic-derived therapeutics to treat major under-treated health problems, has proclaimed an intention to conduct its first-ever clinical trial in human using its MEAI-based CMND-100 compound to treat alcohol use disorder ("AUD").
The Phase I/II unit of the IMCA center in Ramat Gan, Israel, signed the deal. Prof. Mark Weiser, head of the Psychiatric Division at the Sheba Medical Center, whose specialties include cognitive impairment in individuals with psychiatric problems such as substance misuse, depression, and personality disorders, will oversee the trial.
"AUD is very damaging to the individual and her/his family. Because it is so common, it has major implications for public health. CMND-100 has great potential to alleviate this debilitating disorder and improve the quality of life of millions of persons all over the world. This clinical study is a crucial step forward in developing CMND-100, and I am happy to be part of it," says Prof. Mark Weiser.
A study by the National Survey On Drug Use And Health found that, about 28 million persons over 18 struggled with alcoholism in the United States in 2020. In the 18-25 age group, 15.6 percent had AUD, compared to 10.3 percent (or 22.4 million individuals) among those over 25.
According to DelveInsight, the market size for Alcohol Use Disorder therapy in the United States, Italy, Spain, the United Kingdom, Germany, France, and Japan was $564 million in 2021 and is projected to expand by 8.8 percent between 2021 and 2032. Research conducted by the Organization for Economic Co-operation and Development (OECD) revealed that heavy alcohol consumption costs OECD countries approximately $595 billion PPP (Purchasing Power Parity) annually (over 12 grams of alcohol a day for women and 18 grams a day for men). The economic cost occurs from lost work days, alcohol-related diseases, and other alcohol-related side effects.